Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-2214 in Early Alzheimer's Disease
NCT07033494Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- Jul 2025
- Primary completion
- Apr 2029
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 11
01
Overview
A Phase 2 trial of mk-2214 in Alzheimer's disease (AD), sponsored by Merck & Co.. Started Jul 2025; status: recruiting.
02
Drugs
mk-2214
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT07033494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07033494.